RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Quince Therapeutics Stock

Quince Therapeutics ROA 2024

Quince Therapeutics ROA

-0.19

Ticker

QNCX

ISIN

US22053A1079

WKN

A2PHHD

In 2024, Quince Therapeutics's return on assets (ROA) was -0.19, a -62.4% increase from the -0.5 ROA in the previous year.

Quince Therapeutics Aktienanalyse

What does Quince Therapeutics do?

Cortexyme Inc. is a biotechnology company specializing in the development of therapies for degenerative diseases of the nervous system, particularly Alzheimer's disease. The company was founded in 2012 in South San Francisco by Casey Lynch and Stephen Dominy and has since become a leading company in this field. The origin of Cortexyme stems from the discovery of a new bacteria, Porphyromonas gingivalis (P. gingivalis), made by Lynch, the CEO of Cortexyme. He found that P. gingivalis is present in the vicinity of brain plaques in Alzheimer's patients. This discovery meant that Cortexyme had opportunities to develop prevention and treatment options for degenerative diseases of the nervous system. Cortexyme's business model is based on a combination of R&D (research and development) and precision medicine, enabling them to develop personalized therapy approaches. The company is working to specifically target therapeutic molecules against bacteria associated with Alzheimer's and develop biological solutions that target the bacteria. Cortexyme collaborates with a range of specialists, scientists, and university laboratories to conduct their research. The company also has its own research department focused on the discovery of therapeutics to inhibit or eliminate the growth of P. gingivalis. The company has various divisions focusing on the discovery and development of therapeutics. One division focuses on developing biomarkers to aid the diagnosis of Alzheimer's. Another division is developing targeted antibiotics against P. gingivalis, while a third division focuses on developing therapeutics that inhibit the breakdown of bacteria and plaque in the brain. Cortexyme has also developed several products, including the Alzheimer's drug program Atuzaginstat (COR388), which is currently in Phase III of clinical development. Atuzaginstat aims to inhibit P. gingivalis and has the potential to provide hope to terminally ill Alzheimer's patients. Cortexyme is also working on other products, including COR569 to combat inflammation associated with cognitive decline and COR271 to eliminate bacteria that promote brain inflammation. Overall, Cortexyme has taken a new direction in the exploration of Alzheimer's treatment by investigating the role of bacteria in the disease and developing new therapeutic approaches. The company has positioned itself as a leader in Alzheimer's research and will continue to work on developing innovative therapies and prevention strategies that improve the quality of life for Alzheimer's patients and enhance hope for a cure. Quince Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Quince Therapeutics's Return on Assets (ROA)

Quince Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Quince Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Quince Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Quince Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Quince Therapeutics stock

What is the Return on Assets (ROA) of Quince Therapeutics this year?

The Return on Assets (ROA) of Quince Therapeutics is -0.19 undefined this year.

What was the ROA of Quince Therapeutics compared to the previous year?

The ROA of Quince Therapeutics has increased by -62.4% compared to the previous year.

What consequences do high ROA have for investors of Quince Therapeutics?

A high ROA is advantageous for investors of Quince Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Quince Therapeutics?

A low ROA can be unfavorable for investors of Quince Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Quince Therapeutics affect the company?

An increase in ROA of Quince Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Quince Therapeutics impact the company?

A reduction in the ROA of Quince Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Quince Therapeutics?

Some factors that can influence the ROA of Quince Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Quince Therapeutics important for investors?

The ROA of Quince Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Quince Therapeutics take to improve ROA?

To improve ROA, Quince Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Quince Therapeutics pay?

Over the past 12 months, Quince Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Quince Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Quince Therapeutics?

The current dividend yield of Quince Therapeutics is .

When does Quince Therapeutics pay dividends?

Quince Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Quince Therapeutics?

Quince Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Quince Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Quince Therapeutics located?

Quince Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Quince Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Quince Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Quince Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Quince Therapeutics in the year 2023?

In the year 2023, Quince Therapeutics distributed 0 USD as dividends.

In which currency does Quince Therapeutics pay out the dividend?

The dividends of Quince Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Quince Therapeutics

Our stock analysis for Quince Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quince Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.